NCT03216499: A reported trial by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03216499 |
|---|---|
| Title | Single-Arm, Open-Label Phase II Efficacy Study of First-in-Class HIF-2 Alpha Inhibitor, PT2385, for Patients With Recurrent Glioblastoma |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 14, 2017 |
| Completion date | Aug. 31, 2019 |
| Required reporting date | Aug. 30, 2020, midnight |
| Actual reporting date | Aug. 31, 2020 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |